After spending $6.5B for Momenta, J&J readies 'pipeline in a product' for pivotal year

With over 10 indications already being explored and the promise of more to come, it’s no surprise that Johnson & Johnson’s nipocalimab has been dubbed a “pipeline in a product.” It's a good thing, too, because the monoclonal antibody didn't come cheap.